NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress

Earlier in January 2026, Viking Therapeutics reported peer-reviewed Phase 2 VENTURE trial results for its dual GLP‑1/GIP agonist VK2735, showing statistically significant weight loss of up to 14.7% over 13 weeks with generally mild to moderate side effects. With Phase 3 VANQUISH-1 and VANQUISH-2 trials now underway and enrollment largely completed, Viking is moving VK2735 toward longer-term efficacy and safety evaluation in both obesity and type 2 diabetes populations. We’ll now examine how...